Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Mol Carcinog ; 62(9): 1338-1354, 2023 09.
Article in English | MEDLINE | ID: mdl-37378424

ABSTRACT

Osteosarcoma is one of the most common orthopedic malignancies and is characterized by rapid disease progression and a poor prognosis. Currently, research on methods to inhibit osteosarcoma proliferation is still limited. In this study, we found that MST4 levels were significantly increased in osteosarcoma cell lines and tumor tissues compared to normal controls and demonstrated that MST4 is an influential factor in promoting osteosarcoma proliferation both in vivo and in vitro. Proteomic analysis was performed on osteosarcoma cells in the MST4 overexpression and vector expression groups, and 545 significantly differentially expressed proteins were identified and quantified. The candidate differentially expressed protein MRC2 was then identified using parallel reaction monitoring validation. Subsequently, MRC2 expression was silenced with small interfering RNA (siRNA), and we were surprised to find that this alteration affected the cell cycle of MST4-overexpressing osteosarcoma cells, promoted apoptosis and impaired the positive regulation of osteosarcoma growth by MST4. In conclusion, this study identified a novel approach for suppressing osteosarcoma proliferation. Reduction of MRC2 activity inhibits osteosarcoma proliferation in patients with high MST4 expression by altering the cell cycle, which may be valuable for treating osteosarcoma and improving patient prognosis.


Subject(s)
Bone Neoplasms , Osteosarcoma , Humans , Protein Serine-Threonine Kinases/genetics , Proteomics , Osteosarcoma/pathology , RNA, Small Interfering/genetics , Bone Neoplasms/metabolism , Cell Proliferation/genetics , Cell Line, Tumor
2.
MedComm (2020) ; 4(3): e257, 2023 Jun.
Article in English | MEDLINE | ID: mdl-37180822

ABSTRACT

Drug resistance is a major obstacle in cancer treatment and recurrence prevention and leads to poor outcomes in patients suffering from osteosarcoma. Clarification of the mechanism of drug resistance and exploration of effective strategies to overcome this obstacle could lead to clinical benefits for these patients. The expression of far upstream element-binding protein 1 (FUBP1) was found to be markedly elevated in osteosarcoma cell lines and clinical specimens compared with osteoblast cells and normal bone specimens. High expression of FUBP1 was correlated with a more aggressive phenotype and a poor prognosis in osteosarcoma patients. We found that overexpression of FUBP1 confers lobaplatin resistance, whereas the inhibition of FUBP1 sensitizes osteosarcoma cells to lobaplatin-induced cytotoxicity both in vivo and in vitro. Chromatin immunoprecipitation-seq and RNA-seq were performed to explore the potential mechanism. It was revealed that FUBP1 could regulate the transcription of prostaglandin E synthase (PTGES) and subsequently activate the arachidonic acid (AA) metabolic pathway, which leads to resistance to lobaplatin. Our investigation provides evidence that FUBP1 is a potential therapeutic target for osteosarcoma patients. Targeting FUBP1, its downstream target PTGES and the AA metabolic pathway may be promising strategies for sensitizing chemoresistant osteosarcoma cells to lobaplatin.

3.
Bioengineered ; 12(2): 10366-10378, 2021 12.
Article in English | MEDLINE | ID: mdl-34903133

ABSTRACT

Excellent prognostic value of programmed death ligand 1 (PD-L1) is observed in patients with other cancers; however, the prognostic value of PD-L1 in glioblastoma (GBM) remains unclear. Therefore, this meta-analysis evaluated the prognostic value of PD-L1 in GBM. We performed a systematic search in databases to screen eligible articles. The hazard ratio (HR) and 95% confidence interval (95% CI) were extracted from included articles. This meta-analysis included 15 studies, and the forest plot indicated that increased PD-L1 expression was associated with poorer overall survival (OS) of GBM (HR, 1.16; 95% CI, 1.05-1.27; P = 0.002). Furthermore, stratified analysis confirmed that PD-L1 expression was associated with unfavorable OS at the protein level (HR, 1.30; 95% CI, 1.13-1.48; P< 0.001) and messenger ribonucleic acid (mRNA) level (HR, 1.05; 95% CI, 1.00-1.09; P= 0.041). The analysis of a dataset verified the prognostic value of PD-L1 and revealed an association between PD-L1 mRNA expression and the status of isocitrate dehydrogenase (IDH). In conclusion, increased PD-L1 expression predicts unfavorable OS in GBM and may be a promising prognostic biomarker of GBM.


Subject(s)
B7-H1 Antigen/metabolism , Databases as Topic , Glioblastoma/metabolism , Adolescent , Adult , Aged , B7-H1 Antigen/genetics , Child , Female , Gene Expression Regulation, Neoplastic , Humans , Male , Middle Aged , Prognosis , Publication Bias , RNA, Messenger/genetics , RNA, Messenger/metabolism , Reproducibility of Results , Survival Analysis , Young Adult
4.
Front Oncol ; 10: 605737, 2020.
Article in English | MEDLINE | ID: mdl-33381460

ABSTRACT

The overall survival of patients with lower grade glioma (LGG) varies greatly, but the current histopathological classification has limitations in predicting patients' prognosis. Therefore, this study aims to find potential therapeutic target genes and establish a gene signature for predicting the prognosis of LGG. CD44 is a marker of tumor stem cells and has prognostic value in various tumors, but its role in LGG is unclear. By analyzing three glioma datasets from Gene Expression Omnibus (GEO) database, CD44 was upregulated in LGG. We screened 10 CD44-related genes via protein-protein interaction (PPI) network; function enrichment analysis demonstrated that these genes were associated with biological processes and signaling pathways of the tumor; survival analysis showed that four genes (CD44, HYAL2, SPP1, MMP2) were associated with the overall survival (OS) and disease-free survival (DFS)of LGG; a novel four-gene signature was constructed. The prediction model showed good predictive value over 2-, 5-, 8-, and 10-year survival probability in both the development and validation sets. The risk score effectively divided patients into high- and low- risk groups with a distinct outcome. Multivariate analysis confirmed that the risk score and status of IDH were independent prognostic predictors of LGG. Among three LGG subgroups based on the presence of molecular parameters, IDH-mutant gliomas have a favorable OS, especially if combined with 1p/19q codeletion, which further confirmed the distinct biological pattern between three LGG subgroups, and the gene signature is able to divide LGG patients with the same IDH status into high- and low- risk groups. The high-risk group possessed a higher expression of immune checkpoints and was related to the activation of immunosuppressive pathways. Finally, this study provided a convenient tool for predicting patient survival. In summary, the four prognostic genes may be therapeutic targets and prognostic predictors for LGG; this four-gene signature has good prognostic prediction ability and can effectively distinguish high- and low-risk patients. High-risk patients are associated with higher immune checkpoint expression and activation of the immunosuppressive pathway, providing help for screening immunotherapy-sensitive patients.

5.
J Phys Chem B ; 109(32): 15236-42, 2005 Aug 18.
Article in English | MEDLINE | ID: mdl-16852929

ABSTRACT

One-dimensional pure cubic Y(2)O(3)/Eu(3+) nanocrystals (NCs) were synthesized by a hydrothermal method at various temperatures. The NCs prepared at 130 degrees C yielded nanotubes (NTs) with wall thickness of 5-10 nm and outer diameter of 20-40 nm. The NCs prepared at 170 and 180 degrees C yielded nanowires (NWs) with diameters of approximately 100 and approximately 300 nm, respectively. Their luminescent properties, including electronic transition processes, local environments surrounding Eu(3+) ions, electron-phonon coupling, and UV light irradiation induced spectral changes have been systematically studied and compared. The results indicate that the Y(2)O(3)/Eu(3+) NTs and NWs have strong red (5)D(0)-(7)F(2) transitions. The fluorescence lifetime of (5)D(1)-(7)F(1) hardly changes in different samples, while that of (5)D(0)-(7)F(2) decreases a small amount in Y(2)O(3)/Eu(3+) NTs. The (5)D(0)-(7)F(2) lines originate from the emissions of Eu(3+) ions occupying one C(2) site, like that in the bulk powders. The phonon sideline with a frequency shift of 40-50 cm(-1) appears at the low-energy side of the (7)F(0)-(5)D(0) zero phonon line. The relative intensity of the sideline to zero phonon line increases by varying from NTs to NWs, and the spectral position of the phonon sideline shifts red. The UV light irradiation induced spectral change in the charge-transfer band was studied. The results indicate that the spectral change is dependent on sample size and is wavelength selective. A detailed model was proposed to explain the light-induced spectral change.

SELECTION OF CITATIONS
SEARCH DETAIL
...